Vistim Labs announced that its flagship product, Ceregram, is officially ready for launch in U.S. neurology offices in the U.S. Ceregram provides in-office, routine brain imaging, giving physicians and their patients the ability to know when therapy is working.
Ceregram brain images give clear, quantified tracking of changes in brain health, with a level of detail previously only possible through amyloid-PET scans—without the radiation, high cost, or limited access. Ceregram is a noninvasive technology that delivers PET-like brain images that show quantified and localized brain amyloid distributions and intensities, alongside other standard biomarkers, through convenient EEG. This means frequent monitoring—monthly, even weekly—is possible.
